Bausch Health Companies First Quarter 2025 Earnings: EPS Misses Expectations

Bausch Health Companies (NYSE:BHC) First Quarter 2025 Results

Key Financial Results

• Revenue: US$2.26b (up 4.9% from 1Q 2024).
• Net loss: US$58.0m (loss narrowed by 9.4% from 1Q 2024).
• US$0.16 loss per share (improved from US$0.17 loss in 1Q 2024).

Our free stock report includes 1 warning sign investors should be aware of before investing in Bausch Health Companies. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bausch Health Companies EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 7.9% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 3.3% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for Bausch Health Companies you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.